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Background: Many patients with rheumatoid arthritis (RA) achieve disease remission with modern treatment
strategies. However, having achieved this state, there are no tests that predict when withdrawal of therapy will
result in drug-free remission rather than flare. We aimed to identify predictors of drug-free remission in RA.
Methods: The Biomarkers of Remission in Rheumatoid Arthritis (BioRRA) Study was a unique, prospective,
interventional cohort study of complete and abrupt cessation of conventional synthetic disease-modifying anti-
rheumatic drugs (DMARDs). Patients with RA of at least 12 months duration and in clinical and ultrasound
remission discontinued DMARDs and were monitored for six months. The primary outcome was time-to-flare,
defined as disease activity score in 28 joints with C-reactive protein (DAS28-CRP)≥2.4. Baseline clinical and
ultrasound measures, circulating inflammatory biomarkers, and peripheral CD4+ T cell gene expression were
assessed for their ability to predict time-to-flare and flare/remission status by Cox regression and receiver-
operating characteristic (ROC) analysis respectively.
Results: 23/44 (52%) eligible patients experienced an arthritis flare after a median (IQR) of 48 (31.5–86.5) days
following DMARD cessation. A composite score incorporating five baseline variables (three transcripts
[FAM102B, ENSG00000228010, ENSG00000227070], one cytokine [interleukin-27], one clinical [Boolean re-
mission]) differentiated future flare from drug-free remission with an area under the ROC curve of 0.96 (95% CI
0.91–1.00), sensitivity 0.91 (0.78–1.00) and specificity 0.95 (0.84–1.00).
Conclusion: We provide proof-of-concept evidence for predictors of drug-free remission in RA. If validated, these
biomarkers could help to personalize immunosuppressant withdrawal: a therapy paradigm shift with ensuing
patient and economic benefits.
1. Introduction
The past two decades have witnessed a remarkable revolution in
rheumatoid arthritis (RA) outcomes, from a disease of inexorable joint
destruction and disability to one where sustained remission is now a
realistic and achievable treatment target [1]. Many of these advances
have been realised through the effective use of disease-modifying anti-
rheumatic drugs (DMARDs), especially their initiation in the early
phases of disease and escalation in a treat-to-target fashion [2].
Although transformative for patients living with RA, the use of
DMARDs comes at a price. Severe life-threatening toxicity is possible,
including bone marrow suppression and hepatotoxicity [3]. Less severe
but equally debilitating adverse effects are frequently encountered,
such as nausea. Furthermore, the prescription and safety monitoring
requirements are costly for healthcare providers and intrusive to pa-
tients’ lifestyles. There are thus several motivations to consider DMARD
minimisation in the setting of RA remission, a concept which is now
recognised in international RA management guidelines [1,4]. Indeed,
complete cessation of DMARDs is possible, with drug-free remission
(DFR) a well-documented occurrence in 10–20% of patients in long-
itudinal cohorts [5,6].
Interventional studies of complete DMARD cessation in RA suggest
that arthritis flare occurs in approximately half of cases [7–9], a risk
that is likely to be unacceptably high for many patients and clinicians
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owing to the negative impact on quality of life [10,11] and the risk of
cumulative joint damage [12,13] with arthritis flare. Prediction of DFR
vs. flare prior to DMARD withdrawal would help identify patients in
whom DMARD tapering and cessation is more likely to be successful;
however, there are currently no reliable biomarkers of DFR to help
guide clinicians and patients in this setting.
In this study, we present the findings of a prospective interventional
study of complete cessation of conventional synthetic DMARDs in pa-
tients with RA in stable remission. Our aim was to identify biomarkers
across a broad spectrum of domains – clinical, ultrasound, serological,
and transcriptional – which, when measured prior to DMARD cessation,
predict future drug-free remission.
2. Materials and methods
2.1. Recruitment criteria
Eligible patients were identified by their supervising rheumatology
clinical team across five National Health Service (NHS) Trusts in the
North East of England between September 2014 and October 2016.
Patients were eligible for study enrolment if they had a clinical diag-
nosis of RA made at least 12 months previously and were judged to be
currently in clinical remission by their healthcare professional. Only
methotrexate, sulfasalazine and/or hydroxychloroquine therapy was
permitted; patients receiving biologics or any other DMARD in the past
6 months (or 12 months in the case of leflunomide), or glucocorticoids
(enteral, parenteral or intra-articular) in the past 3 months, were ex-
cluded. Patients who were part of another clinical trial, and women
who were planning pregnancy in the next 6 months, were also ex-
cluded.
2.2. Study design
In order to be eligible for DMARD cessation, patients had to be in
clinical remission at the point of study enrolment with no power
Doppler signal on a 7-joint ultrasound examination (see below).
Initially, the 2011 ACR/EULAR Boolean remission criteria [14] were
used to define remission. However, in order to facilitate recruitment
and allow for analysis of baseline ACR/EULAR Boolean remission cri-
teria as a predictor of drug-free clinical remission, this was changed
following study amendment approval to a disease activity score in 28
joints with C-reactive protein (DAS28-CRP) < 2.4 [15,16]. Eligible
patients completely stopped all DMARD therapy without tapering. All
other medications were continued, including non-steroidal anti-in-
flammatory drugs if required. Routine study reviews were scheduled at
month 1, month 3 and month 6, with additional study visits in the case
of suspected flare at patient request. The primary outcome was time-to-
flare, defined as a DAS28-CRP ≥ 2.4 at any time during the six month
follow-up period. A single measure of DAS28-CRP ≥2.4 was permitted
if there was an alternative explanation (e.g. concurrent infection
causing a rise in inflammatory markers) – in these cases, a repeat
DAS28-CRP<2.4 two weeks later was mandatory for continuation in
the study. Patients who experienced an arthritis flare could receive
glucocorticoids (parenteral, intra-articular or enteral) at physician dis-
cretion, before being discharged from the study to rapidly recommence
DMARDs under the guidance of their rheumatologist.
The study design approved by the North East - Tyne & Wear South
Research Ethics Committee (National Health Service Health Research
Authority, reference 14/NE/1042). The study was conducted in ac-
cordance with the Declaration of Helsinki, and all patients provided
informed written consent.
2.3. Clinical variable assessment
A pre-specified list of clinical variables were recorded, with corro-
boration of data by clinical notes review (Supplementary Table S1).
Serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR),
rheumatoid factor (RhF) titre, and anti-citrullinated peptide autoanti-
body (ACPA) titre were measured by the hospital clinical laboratory.
Where CRP levels fell below the detection threshold of the local la-
boratory (< 5mg/L), a value of zero was used for the purposes of
DAS28-CRP calculation.
2.4. Ultrasound (US) assessment
US was performed at study enrolment and month 6 using the same
machine (Xario XG Diagnostic Ultrasound System model SSA-680A,
Toshiba Medical Systems Corporation) by the same operator (KFB) who
is trained in musculoskeletal US assessment. All scans were performed
using the same linear mixed array transducer (part number PLT-
1204BT). B-mode frequency was fixed at 12MHz for all scans, and B-
mode gain was individually set to a level providing optimal contrast
between soft tissue, tendons and bony surfaces, Power Doppler images
were acquired at a Doppler frequency of 5.3MHz for all scans, with
Doppler gain individually set to the maximum level possible without
cortical bone artefact.
A minimum of 30 still images were recorded per scan, corre-
sponding to the individual views of the seven joints of the US7 protocol
of Backhaus et al.: [17] the dominant wrist, 2nd and 3rd metacarpo-
phalangeal joints, 2nd and 3rd proximal interphalangeal joints, and 2nd
and 5th metatarsophalangeal joints. Baseline scans were performed
blinded to the disease activity score. The level of GS at each joint, and
the levels of PD at each joint and tendon complex, were scored using the
semi-quantitative scales (0-3) as per the approach of Scheel et al. [18]
and Szkudlarek et al. [19] respectively. Tendon-associated GS and joint
erosions were scored as either present (1) or absent (0). Minor vessel-
related Doppler signal at the wrist was not scored as power Doppler
signal so long as all of the following criteria were satisfied: a) only a
single vessel was present; and b) the origin of the vessel could be easily
visualised as arising from a vessel superficial to the tendons of extensor
digitorum; and c) no further branching of the vessel occurred below
deep to the tendons of extensor digitorum; and d) the vessel did not
traverse any areas of any level of greyscale change. Such an approach is
in keeping with representative images from a published atlas of mus-
culoskeletal ultrasonographic scoring for use in clinical research [20].
Scan images were rescored by KFB and a second observer (BT) with
good intra- and inter-rater agreement (overall Cohen's kappa 0.73 and
0.62 respectively).
2.5. Laboratory procedures
2.5.1. CD4+ T cell isolation and RNA extraction
CD4+ T cells were isolated from peripheral blood samples by ne-
gative CD36 selection followed by positive CD4 selection as previously
described [21]. The median (IQR, range) purity of CD4+ T cell isola-
tions was 99.0% (98.3–99.3, 95.8–99.7) as confirmed by flow cyto-
metry, with a median (IQR) yield of 2.2 (1.6–2.9) x 105 cells per ml
whole blood. Extracted T cells were then immediately lysed in the
presence of β-mercaptoethanol before freezing at −80 °C. Frozen T cell
lysates were subsequently thawed, and RNA was extracted using the
AllPrep™ DNA/RNA/miRNA Universal Kit (Qiagen) as per the manu-
facturer's instructions. The quantity and quality of RNA in each T cell
lysate was measured by gel electrophoresis using a Tapestation™ 4200
machine (Agilent). The median (IQR, range) RNA yield was 838
(636–976, 277–2275) ng per million cells lysed. The quality of RNA was
excellent, with a median (IQR, range) estimated RNA integrity number
(RINe) of 9.4 (9.1–9.5, 8.7–9.8).
2.5.2. Next-generation RNA sequencing (RNAseq)
1.5 μg of total RNA per sample was used for RNAseq processing;
where total RNA < 1.5 μg, the entire sample was used. Total RNA was
processed using the TruSeq™ Stranded mRNA Library Prep Kit
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(Illumina), according to the ‘High Sample Protocol’ section of the
manufacturer's instructions. RNAseq was performed using an Illumina
NextSeq™ 500 in high-output mode. This configuration delivered 400
million reads over 75 cycles for 40 samples loaded across 4 lanes per
flow cell. Sequencing was performed in batches across 4 separate flow
cell sequencing runs. Samples were allocated to sequencing batches
such that computational correction for any batch-to-batch variation at
the level of either the RNA extraction (6 batches) or RNA sequencing (4
batches) could be achieved, according to a predetermined experimental
design using the duplicate correlation command of the ‘limma’
Bioconductor/R package (v3.32.5) [22]. Samples were sequenced to a
mean (range) depth of 12.1 (9.4–18.4) reads per sample, with excellent
quality demonstrated by a mean Phred score> 30 across all read po-
sitions.
Transcript abundance was estimated from the raw FASTQ files using
Kallisto software (v0.43.0) [23] ran in single-end mode, and using an
index based on Gencode v24 transcript sequences [24]. Read counts
were imported to R (v3.4.1) [25] using the ‘tximport’ package [26],
removing genes with mean read count of< 60. Gene annotation using
the Ensembl GRCh38 assembly [27] was performed using the ‘biomaRt’
package [28]. Read counts were normalised using trimmed mean of M-
values normalisation (TMM), and were then logarithmically trans-
formed to log counts per million (logCPM) using the variance modelling
at the observational level (voom) approach [29]. CD4+ T cell gene
expression data are available at the NCBI Gene Expression Omnibus
(accession number GSE122612).
2.5.3. Serum protein biomarkers
The levels of 39 circulating cytokines, chemokines and acute phase
proteins were measured by electrochemiluminescence (V-PLEX™ plates,
MesoScale Discovery) according to the manufacturer's instructions. All
baseline samples were processed together on the same plates to avoid
batch variation. Assays where<20% of measurements fell above the
lower limit of detection were excluded, leaving 26 biomarkers available
for analysis (Supplementary Fig. S1). Baseline serum protein biomarker
data were unavailable for one patient, who was excluded from the
serum and integrative biomarker analyses.
2.6. Statistical analysis
This was an exploratory study to identify biomarkers for future
validation, and the statistical analyses were conducted in line with this
to prioritize the reduction of type II error. Analysis was performed in
the R environment, version 3.3.2 [25], with additional packages as
specified, according to the following standardised schedule.
First, the association between each variable and time-to-flare was
analysed by univariate Cox regression within each variable domain (i.e.
clinical, ultrasound, serum protein, RNAseq) using the ‘survival’
package [30]. Next, variables were selected based on their univariate p-
value to be taken forward to a multivariate Cox regression model. For
clinical, ultrasound and cytokine data, an elevated significance
threshold (p < 0.2) was used in order to reduce the risk of type II error
at this preliminary stage, in keeping with established precedent
[31,32]. A more stringent significance threshold (p < 0.001) was uti-
lised for RNAseq univariate analysis in reflection of the greater number
of variables analysed. Variables were then advanced to multivariate
Cox regression with backwards stepwise variable selection based on the
Akaike information criterion (using the ‘MASS’ package [14]). Vari-
ables that remained significantly (p < 0.05, or< 0.001 for RNAseq
data) associated with time-to-flare in each domain multivariate model
were then combined in a final multivariate integrative analysis to form
a composite score, weighted by their respective coefficients. No sig-
nificant departure from proportional hazards (as assessed by Schoenfeld
residuals) was observed except where stated. An optimum biomarker
threshold based on Youden's index was then calculated using receiver
operating characteristic (ROC) analysis to assess the sensitivity/speci-
ficity and area under the ROC curve (ROCAUC), with 95% confidence
intervals calculated using bootstrapping (2000 replicates) and the De-
Long procedure respectively (using the ‘pROC’ package [33]). Survival
curves were compared between the dichotomised groups (using the
‘survminer’ package [34]) by the log-rank test as a measure of their
utility in predicting time-to-flare after DMARD cessation.
3. Results
3.1. Patient outcomes
78 patients attended for baseline assessment, of which 44 patients
were eligible for DMARD cessation (Fig. 1). Prior to revision of the
remission criterion by protocol amendment, one patient exited the
study at 69 days despite remaining in DAS28-CRP remission, and was
censored in remission at this time point. Of the patients who dis-
continued DMARDs the majority had established but stable disease, all
were Caucasian, and all satisfied the 2010 ACR/EULAR RA
Fig. 1. Study design and recruitment. 78 patients
attended a baseline visit, of whom 44 stopped dis-
ease-modifying anti-rheumatic drug (DMARD)
therapy. Patients then attended routine study visits at
1, 3 and 6 months following DMARD cessation, with
additional unscheduled visits at the request of the
patient in the event of suspected arthritis flare. Flare
was confirmed if disease activity score in 28 joints
with CRP (DAS28-CRP)≥2.4, at which point the
patient exited the study to restart DMARD therapy
via their referring rheumatology team. Patients who
maintained drug-free remission at 6 months re-
mained without DMARDs and exited the study. PD:
power Doppler.
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classification criteria [35] (Table 1).
23/44 (52%) patients experienced an arthritis flare at a median
(IQR) time to flare of 48 (31.5–86.5) days after DMARD cessation
(Fig. 2). The median (IQR, range) DAS28-CRP score at the time of flare
was 3.12 (2.62–3.94, 1.58–4.51). One patient was classified as flare
despite a DAS28-CRP of 1.58 due to the presence of synovitis (clinical
and ultrasound) in the ankles and feet – discounting this patient gives a
DAS28-CRP range of 2.45–4.51 at the time of flare. A further patient
(who maintained DFR) was treated with a 7 day course of oral pre-
dnisolone by their general practitioner for nasal polyposis at 5 months
after DMARD cessation; no other patients received systemic steroids
during the course of the study.
There were no breaches of study protocol. There were 101 adverse
events recorded, none of which were judged to be a consequence of
DMARD cessation (Supplementary Table S2). There were no serious
adverse events.
3.2. Clinical biomarkers
The association between baseline clinical variables and time-to-flare
Table 1
Baseline demographics of the patients who stopped disease-modifying anti-
rheumatic drugs (DMARDs).
Demographic Patients who stopped
DMARDs (n=44)
Female: n (%) 23 (52)
Age: median (IQR) [range] 66.5 (54.5–71.3) [35–82]
Years since RA diagnosis: median (IQR) [range] 5.5 (3–11) [1–40]
RhF positive: n (%) 25 (57)
ACPA positive: n (%) 25 (57)
RhF or ACPA positive: n (%) 32 (73)
Presence of joint erosion on ultrasound: n (%) 29 (70)
Swollen (28) joint count: median (IQR) [range] 0 (0–0) [0–2]
Tender (28) joint count: median (IQR) [range] 0 (0–0) [0–2]
Patient VAS (mm): median (IQR) [range] 3 (1–10) [0–35]
CRP in mg/L: median (IQR) [range] 0 (0–0) [0–13]
ESR in mm/hr: median (IQR) [range] 9 (2–15) [1–77]a
DAS28-CRP: median (IQR) [range] 1.07 (0.99–1.63) [0.96–2.34]
ACR/EULAR Boolean remission: n (%) 29 (66)
Months since last steroid: median (IQR) [range] 31 (13–48) [4–95]
Months since last change in DMARDs: median
(IQR) [range]
22.5 (12–48.5) [2–132]
Total DMARDs since diagnosis: median [range] 2 [1–4]
Current MTX monotherapy: n (%) 23 (52)
Current SFZ monotherapy: n (%) 4 (9)
Current HCQ monotherapy: n (%) 1 (2)
Current MTX+SFZ: n (%) 5 (11)
Current MTX+HCQ: n (%) 8 (18)
Current SFZ+HCQ: n (%) 1 (2)
Current MTX+SFZ+HCQ: n (%) 2 (5)
ACPA: anti-citrullinated peptide antibody; ACR: American College of
Rheumatology; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate;
EULAR: European League Against Rheumatism; HCQ: hydroxychloroquine;
IQR: interquartile range; MTX: methotrexate; RhF: rheumatoid factor; SFZ:
sulfasalazine.
a : one patient had an elevated ESR of 77 at baseline due to hy-
pergammaglobulinaemia from secondary Sjögren's syndrome.
Fig. 2. Kaplan-Meier plot showing maintenance of drug-free remission following disease-modifying anti-rheumatic drug (DMARD) cessation. Shaded area
depicts the 95% confidence interval.
Table 2
Association of clinical variables with occurrence of arthritis flare following
disease-modifying anti-rheumatic drug (DMARD) cessation, using a backwards
stepwise multivariate Cox regression model.
Variable B HRflare 95% CI p
RhF positive 1.839 6.29 1.61–24.53 0.008
Months since last change in DMARD
therapy
−0.030 0.97 0.95–0.99 0.014
ACR/EULAR Boolean remission −1.330 0.26 0.09–0.77 0.014
Months from first rheumatology review
to starting first DMARD
0.034 1.03 1.01–1.06 0.015
Symptom duration prior to first
rheumatology review (months)
0.063 1.06 1.01–1.12 0.025
Disease duration (years) −0.155 0.86 0.74–1.00 0.043
Current methotrexate 2.261 9.59 0.99–93.29 0.051
Weekly alcohol unit intake 0.050 1.05 0.99–1.11 0.090
ACPA positive 1.078 2.94 0.69–12.48 0.144
For continuous variables, hazard ratios (HR) and the Cox regression coefficients
(B) are presented for a 1-unit change in that variable. Statistical significance
calculated by the Wald test. ACPA: anti-citrullinated peptide antibody; ACR:
American College of Rheumatology; CI: confidence interval; EULAR: European
League Against Rheumatism; RhF: rheumatoid factor.
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was assessed by univariate Cox regression (Supplementary Table S3).
Those with a univariate p < 0.2 were advanced to form a multivariate
stepwise Cox model incorporating 9 baseline clinical variables, of
which 6 were associated with time-to-flare at the p < 0.05 significance
level (Table 2). RhF positivity, longer time from diagnosis to starting
first DMARD, and longer symptom duration at time of diagnosis were
all associated with an increased hazard of flare. In contrast, fulfilment
of ACR/EULAR Boolean remission criteria at baseline, longer time since
last change in DMARD therapy, and longer disease duration were as-
sociated with a reduced hazard of flare.
3.3. Ultrasound biomarkers
Total greyscale synovial, greyscale tenosynovial, and joint erosion
scores were not significantly associated with time-to-flare in univariate
Cox regression analysis (Supplementary Table S4).
3.4. Serum protein biomarkers
Ten serum protein biomarkers were associated with time-to-flare in
univariate Cox regression analyses at a p < 0.2 significance threshold
(Supplementary Table S5). These variables were advanced to multi-
variate Cox regression analysis, and after backwards stepwise selection
reduced to three biomarkers, two of which retained an association
(p < 0.05) with time-to-flare: monocyte chemoattractant protein 1
(MCP1) (HRflare 10.2, 95% CI 2.01–51.4, p= 0.005) and interleukin-27
(IL-27) (HRflare 4.32, 95% CI 1.17–16.0, p= 0.029).
3.5. CD4+ T cell RNAseq biomarkers
The baseline expression of 19 genes within peripheral CD4+ T cells
was associated with time-to-flare in univariate Cox regression analyses
at the p < 0.001 significance threshold (Supplementary Table S6).
From these genes, a multivariate stepwise Cox regression model was
formed incorporating 11 genes, of which three were significant at the
p < 0.001 threshold (Supplementary Table S7). Two of these genes
were associated with an increased hazard ratio (HR) of flare: family
with sequence similarity 102 member B (FAM102B; HRflare 1060, 95%
CI 22.6–50000, p=3.88 x 10−4) and the predicted novel antisense
gene ENSG00000227070 (HRflare 5.94, 95% CI 2.08–16.9, p= 8.63 x
10−4). In contrast, the remaining gene (ENSG00000228010, also a
predicted novel antisense gene) was associated with increased chance
of sustained drug-free remission (HRflare 0.02, 95% CI 0.00–0.14,
p=2.24 x 10−4).
3.6. Integrative biomarker analysis
Based on the aforementioned multivariate analyses, 11 baseline
variables were advanced to a final integrative analysis: six clinical
variables (RhF status, ACR/EULAR Boolean remission, months since
last change in DMARD therapy, symptom duration at diagnosis, disease
duration), two cytokines/chemokines (IL-27, MCP1), and three CD4+ T
cell genes (FAM102B, ENSG00000227070, ENSG00000228010). In a
multivariate backwards stepwise Cox regression model, there was some
evidence for departure from the proportional hazards assumption at-
tributable to minor outlying data for ACR/EULAR Boolean remission
only, although not for the model as a whole (p= 0.36). Five variables
were significantly (p < 0.05) associated with time-to-flare (Table 3),
and were combined with their respective coefficients to form a com-
posite biomarker score:
= ++ +ENSG00000227070FAM102B
ENSG00000228010
Composite biomarker score 1.08( ) 2.90
( ) 2.13(ln[IL27 1])
1.97( ) 1.45(ACR/EULAR Boolean remission)
ROC analysis was used to set an optimum threshold (39.65) for the
prediction of flare following DMARD cessation (Fig. 3A). The composite
biomarker score performed well in predicting arthritis flare, with a
sensitivity of 0.91 (95% CI 0.78–1.00), specificity of 0.95 (0.84–1.00),
positive predictive value of 0.96 (0.86–1.00), negative predictive value
of 0.90 (0.78–1.00), and ROCAUC of 0.96 (0.91–1.00). A negative
composite biomarker score (< 39.65) was a strong predictor of sus-
tained DMARD-free remission, with a significant difference in DMARD-
free survival between those with positive versus negative baseline
scores (p < 0.0001, log-rank test) (Fig. 3B).
To account for reclassification of one patient on grounds of ankle/
feet flare (see Results 3.1 above), a sensitivity analysis was performed
with this patient classified in remission with no notable effect on bio-
marker performance (Supplementary Tables S8 and S9).
4. Discussion
Advances in the management of RA over recent years have made
sustained remission a realistic and achievable goal for many patients.
This has, however, ushered a new dilemma into the clinic: how best to
manage potentially toxic and costly DMARD therapy in such in-
dividuals. There have been several recently published studies of
DMARD tapering in RA remission [36], although the majority focus on
the partial tapering or spacing of biologic agents with continuation of
conventional synthetic DMARDs, rather than addressing the concept of
complete DMARD cessation.
Our unique study design of abrupt and complete DMARD cessation
enabled us to compare baseline characteristics in subsequently flaring
and non-flaring patients. 21/44 (48%) patients maintained clinical re-
mission for 6 months following DMARD cessation, an observation that
is comparable with previously published studies. In the RETRO study,
randomisation to withdrawal (tapering followed by cessation, or im-
mediate cessation) of a variety of biologics and conventional synthetic
DMARDs resulted in DFR (DAS28-ESR < 2.6) in 35/63 (56%) patients
at 12 months, compared to sustained remission in 32/38 (84%) patients
who continued DMARD therapy [8]. In the BeSt study, DFR
(DAS44 < 1.6) was observed in 59/115 (51%) patients who tapered
DMARDs to complete cessation, with a median duration of remission of
23 months [7]. The consistent rate of DFR observed across these studies
is remarkable given the heterogeneity of DMARD therapy, and perhaps
suggests an intrinsic propensity for DFR within disease subtypes that
may be independent of the specific DMARDs initially used to achieve
remission [37]. In this context the relationship between drug-free re-
mission and true immune tolerance deserves further exploration, par-
ticularly because there is a high unmet need for biomarkers to guide
tolerogenic therapy development and implementation [38].
Lower disease activity at the point of DMARD cessation/tapering
was predictive of DFR in several previous studies [5,7,39], in keeping
with the predictive value of ACR/EULAR Boolean remission observed in
Table 3
Association of baseline variables across all domains with time-to-flare following
DMARD-cessation in a backward stepwise multivariate Cox regression model.
Variable B HRflare 95% CI p
ENSG00000228010 −1.972 0.14 0.05–0.37 <0.001
ENSG00000227070 1.080 2.95 1.73–5.01 <0.001
ACR/EULAR Boolean remission −1.446 0.24 0.09–0.61 0.003
ln(IL27 + 1) 2.131 8.43 2.06–34.48 0.003
FAM102B 2.901 18.19 2.26–146.57 0.006
RhF positive 0.729 2.07 0.77–5.60 0.151
For continuous variables, hazard ratios (HR) and the Cox regression coefficients
(B) are presented for a 1-unit change in that variable. Statistical significance
calculated by the Wald test. ACR: American College of Rheumatology; CI:
confidence interval; EULAR: European League Against Rheumatism; FAM102B:
family with sequence similarity 102 member B IL: interleukin; RhF: rheumatoid
factor.
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our study. Interestingly, neither its individual components (i.e.
swollen/tender joint counts, patient global assessment) nor DAS28-CRP
demonstrated predictive value in our study. In contrast, ACR/EULAR
Boolean remission was not predictive of future DFR in the RETRO study
[8]. It is possible that modifications to the ACR/EULAR Boolean con-
struct, such as a relaxation of the patient global assessment threshold
(which has been criticised by some as overly strict [40–46]), may im-
prove its predictive utility in this setting; however, our limited sample
size hinders further exploration.
It is possible that a longer duration of sustained remission prior to
DMARD withdrawal may favour successful achievement of DFR. Higher
rates of DFR are indeed observed with the use of modern treat-to-target
DMARD regimens (where clinical remission is more likely to be
achieved early in the course of disease) compared to historical treat-
ment approaches [6], supporting this assumption. Furthermore, longer
duration of DAS-defined remission was associated with higher rates of
DFR following withdrawal of abatacept in the AVERT study [47], and
lower mean disease activity prior to DMARD withdrawal was predictive
of DFR in BeST [7]. In our study, the lack of a lead-in monitoring period
before DMARD cessation prohibits a direct analysis of the value of re-
mission duration in predicting DFR. Nevertheless, an indirect measure
of remission duration – namely time since last change in DMARD
therapy – is positively associated with achieving DFR, albeit at an in-
sufficient magnitude to advance to the final integrative biomarker
score.
Seronegativity for ACPA and RhF have previously been shown to be
predictive of DFR [5,7–9,48], as observed for RhF in the clinical bio-
marker analysis of our study. In the RETRO study, combination of ACPA
with the 12-cytokine multibiomarker disease activity (MBDA) score
[49] further increased its ability to predict DFR vs. flare following
DMARD cessation [50]. However, in our study ACPA and/or RhF status
did not provide any additional predictive value beyond the five vari-
ables in the final composite biomarker score. We furthermore observe
that IL-27 is associated with increased risk of flare following DMARD
cessation. Indeed, IL-27 has been implicated in the pathogenesis of RA
[51–55], though has also shown protective effects against experimen-
tally-induced arthritis in murine models [56,57]. Our results suggest
that further exploration of the mechanistic role of IL-27 in the context
of arthritis flare may prove valuable.
Our composite biomarker score incorporates the expression of three
genes within peripheral CD4+ T cells. The function of the FAM102B
protein is unknown, although the paralogous FAM102A is known to be
involved in oestrogen signalling [58], osteoclast differentiation [59],
and cell membrane trafficking [60]. ENSG00000228010 is an antisense
RNA gene to zinc finger 12 (ZNF12), a member of the Krüppel C2H2-
type zinc finger family with evolutionarily-conserved function in the
regulation of developmental gene expression [61]. Interestingly, ZNF12
has been implicated as a causative gene in a quantitative trait locus
influencing TNF-α production in vitro by human peripheral blood
mononuclear cells in response to Candida albicans [62], supporting an
immunomodulatory role of the gene. ENSG00000227070 is predicted
to be a novel antisense RNA gene, though no published data exists as to
its putative target (Ensembl genome browser release 95) [63]. To our
knowledge, only one other study has explored differential gene ex-
pression within peripheral CD4+ T cells in the context of DFR in RA.
However, this exploratory analysis of the U-Act-Early study focussed on
differential gene expression at the time of disease diagnosis using a
network analytic approach [64], thus limiting a direct comparison with
our results.
A striking observation is the lack of association of ultrasound bio-
markers with patient outcome following DMARD cessation. However,
to alleviate any potential concerns of referring clinicians, patients with
any degree of power Doppler signal were excluded from DMARD ces-
sation, thus preventing an assessment of this important ultrasound
parameter. Furthermore, significant abnormalities may have been
present outside of the seven joints included within the US7 scan.
Nevertheless, a lack of predictive value of ultrasound in DMARD ta-
pering and cessation was also observed by El Miedany et al. [48], who
found no association between future flare and either greyscale or power
Doppler abnormalities in an extended 40-joint scan protocol.
There are several limitations to this study, notably its small size,
short duration of follow-up, and heterogeneity of DMARDs at enrol-
ment. Over-fitting of the data is likely given that the number of can-
didate variables is greater than the number of study participants, and
the impressive biomarker performance presented herein needs to be
interpreted within this context. Indeed, it is now a priority to validate
our findings in an external cohort, a crucial next step before considering
application to clinical practice.
5. Conclusions
In summary, we describe the integration of variables across multiple
domains (clinical, ultrasound, serological, gene expression) at an un-
precedented resolution to predict DFR in RA. A composite biomarker
Fig. 3. Prediction of flare/remission using the composite biomarker score. (A): Receiver-operating characteristic curve for prediction of flare by the composite
biomarker. The threshold for a positive versus negative test (39.65) is shown by the cross. (B): Kaplan-Meier plot of maintenance of drug-free remission stratified by
positive (red) or negative (blue) baseline composite biomarker score. A significant difference in drug-free remission between the strata was observed (log-rank test).
(For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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score, based on only five baseline variables measured before DMARD
cessation, had excellent predictive value for DFR at 6 months. If suc-
cessfully validated in an external cohort, our biomarker score would
hold promise in identifying those patients for whom drug withdrawal is
appropriate, thus guiding an intelligent and personalised approach to
DMARD therapy in RA remission.
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